KAHR Medical

Executive Summary

KAHR Medical is a preclinical Israeli biotech developing next-generation gene-editing and RNA-based therapeutics for rare genetic disorders and oncology. Leveraging proprietary CRISPR-derived platforms and mRNA delivery technologies, the company aims to address diseases such as muscular dystrophy, cystic fibrosis, and solid tumors with precision medicine. Founded in 2020 and having raised $150 million, KAHR is privately held and operates in Tel Aviv. Its innovative approach combines gene editing for durable correction and RNA therapies for transient modulation, potentially offering safer and more effective treatments. Current efforts focus on advancing lead programs toward clinical development, with key milestones expected within the next 12–18 months.

Upcoming Catalysts (preview)

• Q1 2027IND filing for lead muscular dystrophy program60% success
• H2 2026Proof-of-concept data for cystic fibrosis program50% success
• 2026Strategic partnership or licensing deal for oncology platform40% success